Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Voyager Therapeutics (VYGR) Consolidated Net Income (2016 - 2026)

Voyager Therapeutics' Consolidated Net Income history spans 11 years, with the latest figure at -$27.4 million for Q4 2025.

  • On a quarterly basis, Consolidated Net Income rose 20.47% to -$27.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$119.7 million, a 84.18% decrease, with the full-year FY2025 number at -$119.7 million, down 84.18% from a year prior.
  • Consolidated Net Income hit -$27.4 million in Q4 2025 for Voyager Therapeutics, up from -$27.9 million in the prior quarter.
  • Over the last five years, Consolidated Net Income for VYGR hit a ceiling of $124.0 million in Q1 2023 and a floor of -$34.5 million in Q4 2024.
  • Historically, Consolidated Net Income has averaged -$8.6 million across 5 years, with a median of -$22.9 million in 2022.
  • Biggest five-year swings in Consolidated Net Income: crashed 566.69% in 2022 and later surged 681.85% in 2023.
  • Tracing VYGR's Consolidated Net Income over 5 years: stood at $5.1 million in 2021, then crashed by 566.69% to -$23.6 million in 2022, then skyrocketed by 338.86% to $56.4 million in 2023, then plummeted by 161.15% to -$34.5 million in 2024, then increased by 20.47% to -$27.4 million in 2025.
  • Business Quant data shows Consolidated Net Income for VYGR at -$27.4 million in Q4 2025, -$27.9 million in Q3 2025, and -$33.4 million in Q2 2025.